期刊文献+

雷帕霉素防治冠状动脉再狭窄的研究进展 被引量:4

原文传递
导出
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2003年第9期563-565,共3页 Journal of Clinical Cardiology
  • 引文网络
  • 相关文献

参考文献14

  • 1Abranham R T, Wiederrecht G J. Immunopharmacology of rapamycin. Annu Rev Immunol. 1996,14: 483--510.
  • 2Ruygrok P N, Muller D W, Serruys P W. Rapamycinin cardiovascular medicine. Intern Med J, 2003, 33 : 103-109.
  • 3McMahonLP, ChoiK M, LinT A, et al. The rapamycin-binding domain governs substrate selectivity by mammalian targer of rapamycin. Mol Cell Biol, 2002,22:7428--7438.
  • 4Fingar D C, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP/eIF4E. Genes Dev, 2002, 16: 1472--1487.
  • 5Stawowy P, Blaschke F, Kilimnik A, et al. Proprotein convertase PC5 regulation by PDGF-BB involves PI3-Kinase/p70s6-Kinase activation in vascular smooth muscle cells. Hypertension, 2002,39 : 399--404.
  • 6Hashemolhosseini S, Nagamine Y, Morley S, et al.Rapamycin inhibition of the G1 to S transition is mediated by effets on Cyclin D1 mRNA and proterin stability.J Biol Chem, 1998,273: 14424--14429.
  • 7Klugherz B, Llanos G, Lieuallen W, et al. Stent-based delivery of sirolinus for the prevention of restenosis. J Am Coil Cardiol, 2000,35 :58-- 58.
  • 8Lima V C, Rosa W C, Arruda J A, et al. Efficacy and safety of oral sirolimus to treat and prevent in-stent restenosis: Results of a pilot study. Am J Cardiol,2002,90(Suppl 6A) :11H--11H.
  • 9Degertekin M, Serruys P W, Foley D P, Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation long-term (Up to 2 years) clinical,angiographic, and Intravascular ultrasound follow-up.Circulation, 2002,106: 1610--1613.
  • 10Sousa J E, Costa M A, Sousa A G, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation, 2003, 107:381--383.

同被引文献42

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部